Transcranial magnetic stimulation is associated with reductions in both anxiety and depression scores in patients with both disorders, a large new analysis shows.
Investegate announcements from COMPASS Pathways, COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.